B•WEL RESEARCH bowel cancer and bowel dlsease Anhu?I Report and . Financial Statements For the year ended 31 December 2022 FR FUNDRAISING REGULATOR www.bowelresear¢huk.ory lundralslng@bowelresea￿huk.Ory ,020 3540 8694 ## ## ## ## ## ## Annual Repoitand Finaiicièl stalen￿t5 For Ilieyearended 31 December2022 Research is more than testing new drugs. It means better care. better treatments with medicines. better surgeryll better support. better quality of life and better chances of survlval. ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## B•WEL RESEARCH UK. Let's end bowel cancer and bowel dlsease Financial Review www.bowelresearchuk.ory ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## B•WEL RESEARCH UK. Let's end bowel cancer and bowel dlsease Financial Statements For the year ended 31 December 2022 www.bowelresearchuk.org ## ## ## ## ## ## ## ## |
forthe year ended 31Decemb|
er 2022|||| |---|---|---|---|---| |||Restricted|Unrestricted|Total| |||funds|funds|funds| ||Note|2022
f|2022f|2022f| |Income from:||||| |Donations and legacies||890,926|120,494|1,011,420| |Charitable
Income||9,132||9,132| |Investments||25,960||25,960| |Totallncome||926,018|120,494|1,046,512| |Exlsendlture on:||||| |Raising Funds||(254,376)||(254,376)| |Charitable activities|5|(456,201)||(456,201)| |Total expenditure||(710,577)||(710,577)| |Net income||215,441|120,494|335,935| |Other recognised gains and losses||||| |Other gains/losses||(128,789)||(128,789)| |Net movement
Infunds||86,652|120,494|207,146| |Reconciliation offunds||||| |Total Funds brought forward||348,470|235,326|583,796| |Total funds carried forward|19|435,122|355,820|790,942| ## |forthe year ended|3'i Decem|ber 2021|||| |---|---|---|---|---|---| ||||Restricted|Unrestricted|Total| ||||funds|funds|funds| |||Note|2021f|2021f|2021f| |income from:|||||| |Donations
and legacies|||699,617|158,765|858,382| |Charitable
Income|||85,540||85,540| |Investments|||29,198||29,198| |Total income|||814,355|158,765|873,120| |Expenditure
on:|||||| |Raising Funds|||(217,413)||(217,413)| |Charitable
activities||5|(895,552)|(66,)69)|(961,721)| |Total expenditure|||(1,112,965)|(66,168)|(1,179,134)| |Gains/(losses)
on investment|assets||83,475||83,475| |Net (expenditure)/income|||(2)5,135)|92,596|(i22,539)| |Transfers between
funds|||40,600|(40,600)|| |Net movement
in funds|||86,652|120,494|207,146| |Reconciliation offunds|||||| |Total Funds brought forward|||348,470|235,326|583,796| |Total funds carried forward||19|435,122|355,820|790,942| ## |
asat31Dec|
emb|
er 2021|||| |---|---|---|---|---|---| ||||Note|2022f|2021f| |Fixed assets|||||| |Tangible assets|||11|115|2,339| |Investments|||12|810,101|938,890| |||||810,216|941,229| |Current assets|||||| |Debtors|||13|180,806|247,206| |Cash at bank and in hand||||1,269,266|1,286,651| |||||2,286,033|1,533,857| |Creditors: amounts|falling|due within one year|14|(1,204,613)|(1,403,211)| |Net current assets||||245,459|130,646| |Total assets less|current liahilitles|||1,055,675|1,071,875| |Creditors: amounts|falling|due after more than one year|15|(264,733)|(488,079)| |Net assets excluding||pension asset||790,942|583,796| |Funds ofthe charity:|||||| |Restricted funds||||355,820|235,326| |Unrestricted
funds||||435,122|348,470| |Total funds|||19|790,942|583,796| ## |forthe year|ended|
31December 2022|||| |---|---|---|---|---|---| |||||2022|2021| ||||Note|5|E| |Cash ttows from|operatins|activities|||| |Net cash income/(expenditure)||||207,146|(122,539)| |Adjustments
to|cash flows|from non-cash items|||| |Depreciation||||2,224|1,879| |Investment
income|||4|(25,960)|(29,198)| |Net losses/(gains)|on investments|||128,789|(83,475)| |||||312,199|(233,333)| |Working capital|adjustments||||| |Decrease/(increase)|in debtors||13|66,400|(115,407)| |(Decrease)/increase|in creditors||14|(421,944)|147,460| |Net cash flows from operating||activites||(43,345)|(201,280)| |Cash flows from|Investing|activities|||| |Interest receivable||||25,960|29,198| |Net decrease
in cash and cash||equivalents||(17,385)|(172,082)| |Cash and cash equivalents
at 1||January||1,286,65|1,458,733| |Cash and cash equivalents
at 31 December||||1,269,266|1,286,651| ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## |2.Income from|donations and legacie|s||| |---|---|---|---|---| |||Restricted|Unrestricted|Total| |||funds|funds|funds| |||2022f|2022f|2022f| |Donations||454,455|500|454,955| |Legacies||428,201||428,201| |Grants||8,270|119,994|128,264| |||890,926|120,494|1,011,420| |||Restricted|Unrestricted|Total| |||funds|funds|funds| |||2021
f.|2021f|2021f| |Donations||508,135||508,135| |Legacies||81,345||81,345| |Grants||110,137|158,765|268,902| |||699,617|158,765|858,382| |3.Income from|charitable activities|||| ||||Unrestricted|Total| ||||funds|funds| ||||2022
f.|2022f| |Research|||9,132|9,132| ||||Unrestricted|Total| ||||funds|funds| ||||2021f|2021f| |Research|||85,540|85,540| |4.Investment|income|||| |||Restricted|Unrestricted|Total| |||funds|funds|funds| |||2022f|2022f|2022f| |Dividends||25,846||25,846| |Interest||114||114| |||25,960||25,960| |||Restricted|Unrestricted|Total| |||funds|funds|funds| |||2021f|2021f|2021| |Dividends||29,198||29,198| |||29,198||29,198| ## |charitab|le activities|||| |---|---|---|---|---| |Summary|by fund type|Unrestricted|Restricted|Total| |||funds|funds|funds| |||2022f|2022f|2022f| |Direct costs||25,515||25,515| |Research||112,202||112,202| |Grant funding ofactivities||206,825||206,825| |Allocated support costs||111,659||111,659| |||456,201||456,201| |Summary|by fund type|Unrestricted|Restricted|Total| |||funds|funds|funds| |||2021
f.|2021f|2021f| |Direct costs||21,299||21,299| |Research||118,282||118,282| |Grant funding ofactivities||567,485|66,169|633,654| |Allocated support costs||188,486||188,486| |||895,552|66,169|961,721| ## |Annual
Report and Ftnanaai Statements
For the year ended 31 December 2022
6.Grants Awarded||||| |---|---|---|---|---| ||||Total|Total| ||||2022f|2021f| |Percutaneous
infracoccygeal
Botulinum
toxin injection for treatment
dyssynergic
defaecation||of||4,103| |Development
ofa blood test tofind early signs ofcolorectal cancer
people with inflammatory
bowel disease||in||75,000| |New strategies
for improving
radiotherapy
response
in bowel cancer||||74,919| |Investigating
variations
in two genes that increase the risk ofbowel||cancer||74,574| |Utility ofMotility-MIR
in the assessment
ofFeorgut Neuromuscular
in children
with Paediatric
Intestinal
Pseudo-Obstruction||Function||50,000| |Identify new strategies to prevent
immune
cells supporting
liver metastasis
in colorectal cancer||||50,000| |Treatment
pathway to improve bowel control after bowel resection
colorectal cancer||for||50,000| |Effectiveness ofan Acceptance and Commitment
Therapy based||||| |psychological
intervention
on reducing
psychological
distress
in those
diag nored with Gastro-intestinal
Dysmotility||||49,994| |Understanding
how immune
dysfunction
impacts ulverative
colitis
human
mini colons||using||49,708| |Causes ofrare and severe complications
ofPaediatric Inflammatory
Disease||Bowel||49,013| |Investigating
the role ofbacteria-infecting
viruses
in inflammatory
disease|bowel|||48,950| |IBDSelf management||||46,186| |Decision-making
in complex pelvic exentreration
surgey for patients with
locally advanced
or recurrent
rectal cancer||||39,923| |International
collaboration
to improve
management
ofpatients with rare||||| |retrorectal
tumors||||18,007| |Laparoscopy orAntibiotics
for Managing
Appendicitus||||16,205| |Marshall Wave|||15,000|| |Parastomal
hernia and shared decision making|||107,579|| |Identification
ofspatial biomarkers
in colorectal cancer|||84,246|| |Grants withdrawn||||(62,928)| ||||206,825|633,654| ## ## |||||2022|2021| |---|---|---|---|---|---| |||||No|No| |Employees||||5|5| |1he number ofemployees whose employee|benefits (excluding|employer|pension|costs) exceeded f60,00was:|| |||||2022|2021| |||||No|No| |580,001 - E90,000|||||1| ## |Director ofFundraising|and Director of|Re|search|.||| |---|---|---|---|---|---|---| ||||||2022f|2021
E| |Wages and Salaries|||||155,376|301,969| |Social security costs|||||11,471|33,094| |Contribution todefined contrlbutlon|||pension schemes||5,853|13,836| ||||||172,700|348,899| |During the year there were termination||payments||made which amounted|tofNil (2021-E26 585).There|was ENil| |(2021 - ENil) outstanding|atthe end ofthe||year.|||| |9.Auditors'
remuneration||||||| ||||||2022|2021| ||||||E|f.| |Fees payable tothe|auditor forthe audit|||ofthe annual costs|8,400|7,350| |Preparation
ofthe financial statements|||||2,040|1,825| ||||||10,440|9,175| ## ## |The charity is a registered
charity and istherefore exe
applicable to charitable
purposes
only.
S.Tangible fixed assets|mpt from taxation to the extent that it's income and|gains are| |---|---|---| ||Offlce|| ||Equipmentf|Totalf| |Cost||| |At1 January 2022|6,671|6,671| |At 31December 2022|6,671|6,671| |Depreciation||| |At 1 January
2022|4,332|4,332| |Charge for the year|2,224|2,224| |At 31 Deceber 2022|6,556|6,556| |Net book value||| |At 31December 2022|115|115| |At 31December 2021|2,339|2,339| |12.Fixed asset investments||||| |---|---|---|---|---| ||||Listed|| ||||Investmentsf|Totalf| |Costorvaluation||||| |At 1January 2022|||938,890|938,890| |(Losses)|||(128,789)|(128,789)| |At 31 December 2022|||810,101|810,101| |Net book value||||| |At 31 December 2022|||810,101|810,101| |At 31 December 2021|||938,890|938,890| |13.Debtors||||| ||||2022f|2021f| |Trade debtors|||2,946|13,226| |Prepayments
and accrued income|||177,860|233,553| |Other debtors||||427| ||||'IS0,606|247,206| |12.Fixed asset investments||||| ||||2022f|2021f| |Trade creditors|||115,302|143,906| |PAVE/NIC|||5,569|| |Grants payable|||1,062,127|1,209,458| |Accruals and deffered income|||21,615|49,847| ||||1,204,613|1,403,211| |The balance ofdeffered income is recognised|based on the following:|||| ||||2022
f.|2021f| |Deffered income at 1January 2022|||18,265|88,694| |Amounts
released from previous periods|||(8,270)|(70,429)| |Deferred income atyear end|||9,995|16,265| |Deffered income relates to grant income received||in advance ofthe work being|performed.|| |12.Creditors: amounts falling||due after one year||| ||||2022f|2021| |Grants payable|||264,733|488,079| ## |16.Reconcili|ation|ofgrants payable||| |---|---|---|---|---| ||||2022f|2021f| |Grants commitment|b/fwd|1January 2022|1,697,537|1,543,574| |Commitments
made in the||period|206,825|696,582| |Grants paid during the period|||(577,502)|(479,691)| |Grant commitments|withdrawn|||(62,928)| |Grant commitments|atyear|end|1,326,860|1,697,537| ## ## ## ## ## |||||||Other|| |---|---|---|---|---|---|---|---| ||||Balance at|||recosnlsed|Balance at| ||||1January|||Gains/|31December| ||||2022
5|Incomef||(Losses)
5|2022
5| |Unrestricted|funds||||||| |General Funds|||348,470|926,018|(710,577)|(128,789)|435,122| |Restricted funds|||||||| |PhD fund-|||||||| |Ulcerative
Colitis|||49,726||||49,726| |Role ofAdam 17|||||||| |in the gut|||3,813||||3,813| |Lucy Thomas Fund|||20,560||||20,560| |Robin Charitable||Trust|11,000||||11,000| |Nasbo Project Funding|||1,880||||1,880| |David and Ruth|Lewis||||||| |Charitable
Trust|||3,000||||3,000| |ELFStudy|||7,000||||7,000| |Catherine Cookson|||10,000||||10,000| |Sylvia and Colin|||||||| |Shepherd
CT|||500||||500| |NSW Davidson|||20,000||||20,000| |Kendrick and Sylvia|||||||| |Edwards||||500|||500| |Borelli||||50,000|||50,000| |Twist||||49,994|||49,994| |Steel Charitable||Trust||10,000|||10,000| |ACPGBI||||10,000|||10,000| |The Medical Research|||||||| |Council|||107,847||||107,847| |Total|||||||| |Restricted funds|||235,326|120,494|||355,820| |Totaloffunds|||583,796|1,046,512|(710,577)|(128,789)|790,942| ## ## ||||Atdate||||||| |---|---|---|---|---|---|---|---|---|---| ||||BRVK|||||Other|| ||||became|||||recognised|Balance at| ||||sole||||Transfers|Galas/ 31December|| ||||member
5|Income
E|Expenditure|f|ln/out
E|(Losses)
E|2022
8| |Unrestricted
funds|||||||||| |General Funds|||523,005|814,355|(1,112,965)||40,600|83,475|348,470| |Restricted funds|||||||||| |PhD fund|||65,169||(65,169)||||| |PhD fund-|||||||||| |Ulcerative
Colitis|||49,726||||||49,726| |Role ofAdam 17|||||||||| |in the gut|||3,813||||||3,813| |Lucy Thomas Fund|||11,742|8,818|||||20,560| |Graham
Kirkham|||||||||| |Foundation|||5,000||||(5,000)||| |KMcDonald|||||||||| |General Charitable||Trust|5,000||||(5,000)||| |Robin Charitable|Trust||11,000||||||11,000| |Nasbo Project Funding|||'I,880||||||1,880| |David and Ruth Lewis|||||||||| |Charitable
Trust|||3,000||||||3,000| |ELFStudy|||7,000||||||7,000| |David
Br Ruth Lewis||||26,600|||(26,600)||| |Hospital Saturday||Fund||2,000|||(2,0001||| |G W Turner Trust||||2,000|||(2,000)||| |M Jackson||||1,000|(1,000)||||| |Catherine
Cookson||||10,000|||||10,000| |Sylvia and Colin|||||||||| |Shepherd
CT||||500|||||500| |NSW Davidson|||20,000||||||20,000| |The Medical Research|||||||||| |Council||||107,847|||||107,847| |Total|||||||||| |Restricted funds|||183,330|158,765|(66,169)||(40,600)||235,326| |Totaloffunds|||706,335|973,120|(1,179,134)|||83,475|583,796| ## ## ## |20.Analysis ofnet assets bet
Analysis ofnet assets between funds|ween funds||| |---|---|---|---| ||Unrestricted||Total funds at| ||funds|Restricted|31December| ||Generalf|fundsf|2022| |Tangible fixed assets|115||115| |Fixed asset investments|810,101||810,101| |Current assets|1,094,252|355,820|1,450,072| |Creditors due within one year|(1,204,613)||(1,204,613)| |Creditors due in more than one year|(264,733)||(264,733)| |Total|435,122|355,820|790,942| ||||Total funds at| ||Unrestricted|Restricted|31December| ||fundsf|fundsf|2021f| |Tangible fixed assets|2,339||2,339| |Fixed asset investments|938,890||938,890| |Current assets|1,298,531|235,326|1,533,857| |Creditors due within one year|(1,403,211)||(1,403,211)| |Creditors due in more than one year|(488,079)||(488,079)| |Total|348,470|235,326|583,796| ## ## ## ## ## BIl)WEL RESEARCH UK. c/oThe Royal College ofsurgeons ofEngland 35-43 Lincoln's Inn Fields London WC2A 3PE www.bow•lresearchuk.org ReglsteredCharftyNo1l86C61, incorporated andregi%teredin En9land8ndWa￿,